Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07116746 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
A Phase 2 study of Gout and Hyperuricemia, sponsored by Arthrosi Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 8
- Study locations
NCT07116746 is a Phase 2 study of Gout and Hyperuricemia that is actively recruiting participants, run by Arthrosi Therapeutics. The registered enrollment target is 25 participants, below the 8,888-participant average among 34 other Gout trials with a reported enrollment target (100% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT07116746, a Phase 2 study of Gout and Hyperuricemia, is actively recruiting participants, sponsored by Arthrosi Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibody development, and/or at least one sUA level that rose to greater than 6 mg/dL while on therapy.
Conditions Studied
Interventions
- DRUG AR882 75 mg
- DRUG XOI Low Dose
- DRUG XOI High Dose
Study Locations (8)
Florida
- Arthrosi Investigative Site (105) - Margate
- Arthrosi Investigative Site (102) - Miami
- Arthrosi Investigative Site (109) - Tampa
Mississippi
- Arthrosi Investigative Site (106) - Jackson
North Carolina
- Arthrosi Investigative Site (108) - Charlotte
Pennsylvania
- Arthrosi Investigative Site (103) - Duncansville
Texas
- Arthrosi Investigative Site (104) - West Lake Hills
Washington
- Arthrosi Investigative Site (107) - Bellevue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07116746
The ClinicalTrials.gov registry entry for NCT07116746 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 8,888-participant average among 34 other Gout trials with a reported enrollment target (100% lower). The listed sponsor is Arthrosi Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Gout appearing as the primary indexed condition, and to 3 interventions - of which AR882 75 mg is the first listed.
NCT07116746 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Florida, Mississippi, North Carolina.
Frequently Asked Questions
What is clinical trial NCT07116746 about?
NCT07116746 is a clinical study titled "Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients". This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibo...
What is the current status of trial NCT07116746?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-12-03. Estimated completion is 2027-01.
What conditions does trial NCT07116746 study?
This clinical trial studies the following conditions: Gout, Hyperuricemia, Gout Chronic, Uncontrolled Gout, Gouty Arthritis.
What interventions are being tested in trial NCT07116746?
The interventions under investigation include: AR882 75 mg (DRUG), XOI Low Dose (DRUG), XOI High Dose (DRUG).
Who is sponsoring clinical trial NCT07116746?
This trial is sponsored by Arthrosi Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07116746 being conducted?
This trial has 8 study locations across Florida, Mississippi, North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
RECRUITING · Phase 2
-
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
RECRUITING · Phase 2
-
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
ACTIVE NOT RECRUITING · Phase 2
-
Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.
ACTIVE NOT RECRUITING · Phase 2
-
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
COMPLETED · Phase 2
-
Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.